Table 1.
Single cell mutation analysis of CTCs
| Patient ID | Sample ID | Sample type | Number CTCs analyzed/total CTCs collected* | Number CTCs with PIK3CA exon 9 mutation | Number CTCs with PIK3CA exon 20 mutation |
|---|---|---|---|---|---|
| 1 |
1-1 |
Blood |
3/13 |
0 |
0 |
| 1 |
1-2 |
Blood |
3/9 |
0 |
0 |
| 1 |
1-3 |
Blood |
4/9 |
0 |
0 |
| 2 |
2-1 |
Blood |
3/20 |
0 |
0 |
| 2 |
2-2 |
Blood |
2/6 |
0 |
0 |
| 2 |
2-3 |
Blood |
5/50 |
0 |
0 |
| 3 |
3-1 |
Blood |
3/14 |
0 |
0 |
| 4 |
4-1 |
Blood |
2/8 |
0 |
0 |
| 5 |
5-1 |
Blood |
2/3 |
0 |
0 |
| 6 |
6-1 |
Blood |
8/75 |
0 |
0 |
| 7 |
7-1 |
Blood |
5/100 |
0 |
0 |
| 8 |
8-1 |
Blood |
5/60 |
0 |
0 |
| 9 |
9-1 |
Blood |
2/7 |
0 |
0 |
| 10 |
10-1 |
Blood |
5/200 |
0 |
0 |
| 11 |
11-1 |
Blood |
5/50 |
0 |
0 |
| 12 |
12-1 |
Blood |
3/6 |
0 |
0 |
| 12 |
12-2 |
Blood |
2/2 |
0 |
0 |
| 12 |
12-3 |
Blood |
4/4 |
0 |
0 |
| 12 |
12-4 |
Blood |
13/13 |
0 |
0 |
| 12 |
12-5 |
Blood |
20/20 |
10 |
0 |
| 12 |
12-6 |
Blood |
7/9 |
2 |
0 |
| 12 |
12-7 |
Blood |
27/27 |
0 |
ND |
| 12 |
12-8 |
Blood |
50/50 |
0 |
ND |
| 12 |
12-9 |
Blood |
0/0 |
- |
- |
| 12 |
12-10 |
Blood |
2/2 |
0 |
0 |
| 13 |
13-1 (BL) |
Blood |
0/0 |
- |
- |
| 14 |
14-1 (BL) |
Blood |
0/6 |
- |
- |
| 15 |
15-1 (BL) |
Blood |
0/6 |
- |
- |
| 16 |
16-1 (BL) |
Blood |
0/0 |
- |
- |
| 17 |
17-1 (BL) |
Blood |
0/0 |
- |
- |
| TOTALS | |||||
| 17 patients | 30 samples | - | 185/769 | 12 | 0 |
CTCs circulating tumor cells, ND not determined.
*CTCs not analyzed for mutations were used for transcriptional analysis [21], immunostaining, or other molecular assays.